LabAutomation 2006 - SLAS

LabAutomation2006
4:30 pm Monday, January 23, 2006 Track 5: Frontiers Beyond BioPharma Room: Sierra/Ventura
Wyndham Palm Springs Hotel
Richard Murante
Integrated Nano-Technologies, LLC
Henrietta, New York
rmurante@integratednano.com
An Electronic Nucleic Acid Detector for the Identification of Biological Agents
Integrated Nano-Technologies (INT) is working to produce a field-portable, non-PCR-based DNA biosensor. This biosensor will couple the
sensitivity and specificity of DNA hybridization with direct electronic detection to identify pathogens without the need for prior amplification
of the DNA. The most innovative feature of this biosensor is that it uses the combination of a biological event (hybridization) with
microelectronics to electronically detect the presence of a specific target DNA.
INT’s DNA biosensor consists of oligonucleotide probes attached to multiple pairs of interdigitated electrodes on a microchip. Biological
samples are processed to produce a solution of DNA fragments which is passed over the biosensor surface. Hybridization of a target
fragment with capture probes forms a DNA bridge connecting the two electrodes. Chemical treatment of this bridge converts it to a
conductive wire. Hybridization is then able to be detected by measuring the change in electrical resistance across the electrodes. Most
recent research and development work on INT’s biosensor system has focused on improving both the biological and chemical reactions
required for the detection of low levels of target DNA molecules.
By providing a fast, accurate and low-cost means of detection of biological agents such as anthrax, smallpox, hepatitis, SARS,
salmonella and others, considerable opportunities exist for INT’s technology in bio-warfare and bio-terrorism defense, clinical diagnostics,
environmental testing, and food safety.
10:30 am Tuesday, January 24, 2006 Track 5: Frontiers Beyond BioPharma Room: Sierra/Ventura
Wyndham Palm Springs Hotel
Jonathan Dordick
Co-Author(s)
Rensselaer Polytechnic Institute
Douglas S. Clark,
Troy, New York
University of California, Berkeley
dordick@rpi.edu
Moo-Yeal Lee, Solidus Biosciences
Anand Ramasubramanian, University of California, Berkeley
Michael Hogg, Solidus Biosciences
Metabolizing Enzyme Toxicology Assay Chip (MetaChip) for High-Throughput
Microscale Toxicity Analyses
The clinical progression of new chemical entities to pharmaceuticals remains hindered by the relatively slow pace of technology
development in toxicology and clinical safety evaluation, particularly in vitro approaches, that can be used in the preclinical and early
clinical phases of drug development. To alleviate this bottleneck, we have developed a Metabolizing Enzyme Toxicology Assay Chip
(MetaChip) that combines high-throughput P450 catalysis with cell-based screening on a microscale platform. The MetaChip provides a
high-throughput microscale alternative to currently used in vitro methods for human metabolism and toxicology screening based on liver
slices, cultured human hepatocytes, purified microsomal preparations, or isolated and purified P450s. This novel technology creates new
opportunities for rapid and inexpensive assessment of ADME/Tox at very early phases of drug development, thereby enabling unsuitable
candidates to be eliminated from consideration much earlier in the drug discovery process.
94
F I N A L I S T